louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01601158: Umbilical Cord Blood Therapy for Children With Global Developmental Delay
Official title: Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Children With Global Developmental Delay
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Global Developmental Delay
Keywords: Global developmental delay
Umbilical cord blood
Rehabilitation
Lead sponsor: Bundang CHA Hospital
Sponsor class: OTHER
First posted: 2012-05-17
Enrollment: 10
Sex: ALL
Minimum age (years): 6
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This open-label study aims to evaluate the safety and efficacy of umbilical cord blood therapy for children with global developmental delay.

Detailed description: Global developmental delay (GDD) is a subset of developmental disabilities defined as significant delay in two or more of the following developmental domains: gross/fine motor, speech/language, cognition, social/personal, and activities of daily living.

Umbilical cord blood has been used for inherited metabolic diseases that feature global developmental delay and many experimental animal studies have revealed umbilical cord blood is useful to repair neurological impairments in brain.

Eligibility criteria: Inclusion Criteria:

* Global developmental delay
* Willing to comply with all study procedure

Exclusion Criteria:

* Medical instability including pneumonia or renal function at enrollment
* Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
* Uncontrolled persistent epilepsy
* Not eligible according to the principal investigator

Primary outcomes:
measure: Changes in Cognition
timeFrame: Baseline - 6 months - 12 months
measure: Changes in Cognitive Neurodevelopmental Outcome
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
Secondary outcomes:
measure: Changes in Motor Performance
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
measure: Changes in Standardized Gross Motor Function
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
measure: Changes in Motor Neurodevelopmental Outcome
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
measure: Changes in Functional Independence in Daily Activities
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
measure: Changes in Visual Perception Test
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
measure: Changes in Muscle Strength
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
measure: Changes in Functional Performance in Daily Activities
timeFrame: Baseline - 1 month - 3 months - 6 months - 12 months
measure: Changes in Language Evaluation
timeFrame: Baseline - 6 months - 12 months
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: CHA Bundang Medical Center, CHA University
state: Gyeonggi-do
Study officials:
affiliation: CHA University
name: Minyoung Kim, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00773058: Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS)
Official title: Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Acute Respiratory Distress Syndrome
Adrenal Insufficiency
Keywords: acute respiratory distress syndrome
glucocorticoid
adrenal insufficiency
Lead sponsor: Southeast University, China
Sponsor class: OTHER
Collaborators: name: Nanjing Medical University
First posted: 2008-10-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if stress doses of hydrocortisone improve early outcome in patients who are in early stage of ARDS and with relative adrenal insufficiency.


Eligibility criteria: Inclusion Criteria:

* within the first 3 days of onset of clinically definite ARDS confirmed by AECC criteria in 1994
* 18 to 85 year old

Exclusion Criteria:

* pregnancy or lactation
* tumor or other immunologic disease
* immunosuppressive drug used
* bone marrow or lung transplantation
* primary or secondary disease of adrenal gland
* hormone used within 3 months
* refusing conventional therapy
* be in other clinical tests within 30 days

Primary outcomes:
measure: Evidence of clinically definite ARDS confirmed by AECC criteria in 1994
timeFrame: within the first 3 days after surgery onset of ARDS
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06931158: HOnest Placebos With Explanations: Evaluating Open-Label Placebos for Chronic Pain
Official title: Optimizing Open Placebos for Chronic Pain Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Low-back Pain
Chronic Pain
Keywords: open-label placebo
rationales
placebo effect
Lead sponsor: Rhode Island Hospital
Sponsor class: OTHER
First posted: 2025-04-17
Enrollment: 340
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to examine the effect of rationale condition when taking open-label placebos on pain by 1) comparing each rationale to the no rationale control condition and the no treatment control condition; and 2) comparing the rationale conditions to each other. We also aim to examine the effect of rationale condition on prescription opioid use by 1) comparing each rationale to the no rationale control condition and the no treatment control condition; and 2) comparing the rationale conditions to each other.

This study will include patients with chronic low back pain. The main question it aims to answer is:

How do rationales influence the effects of open-label placebos?

Researchers will compare different rationales given when taking an open-label placebo and a no-treatment group and a no rationale group taking OLPs.


Eligibility criteria: Inclusion criteria are:

* chronic pain (pain lasting at least 3 months, pain intensity 4/10 or over and interference 3/10 or over)
* at least 18 years old
* English speaking
* have a smartphone or computer with video access
* the chronic pain is concentrated into the patient's lower back (tentative criteria based on recruitment rate)

Exclusion Criteria

* Have chronic pain because of a cancer diagnosis
* Over 89 years of age
* Suspect an allergy to any placebo ingredient
* Currently receiving worker's compensation.

Primary outcomes:
measure: Pain intensity
timeFrame: across 42 days
Secondary outcomes:
measure: Pain interference
timeFrame: across 42 days
measure: Pain catastrophizing
timeFrame: across 42 days
measure: Prescription Medication use (including opioids)
timeFrame: across 42 days
Other outcomes:
measure: Placebo use
timeFrame: across 21 days
Locations:
city: Providence
country: United States
facility: Rhode Island Hospital
state: Rhode Island
Study officials:
References:
Clinical trial NCT00459758: Effect of Electrical Stimulation at Acupoints on Blood Pressure
Official title: Pilot Study Using Electrical Stimulation on Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Keywords: hypertension
Hans
Electrical stimulation
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2007-04-12
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine if electrical stimulation on acupoints has any effect on hypertensive subjects.

Detailed description: All subjects will be assigned into control and experimental groups by a random table. The first 40 numbers in the first row will be used for the study. Subjects assigned with an odd number will be divided into the control group.

ROLE OF SUBJECTS Subjects in the experimental will receive Hans treatment for hypertension. No invasive procedures will be used for subjects in either the control and experimental groups.

This randomized controlled study will recruit hypertensive subjects into control and experimental groups using a random table. Only the subjects in the experimental group use Hans stimulation as a treatment for high blood pressure. The treatment regiment is discussed in the Treatment section in detail. The subjects in the control group will not

Eligibility criteria: Inclusion Criteria:

* Diagnosis of mild hypertension (160-140/100-90 mmHg), male and female subjects with any racial background will be invited to participate in the study.
* All adult age groups are included in the study.
* Subjects must sign an informed consent form.

Exclusion Criteria:

* Diagnosis of severe hypertension (200-161/120-101 mmHg), limited physical activity, heart failure, kidney diseases and mental diseases are excluded in the study. A questionnaire will be used in the initial patient screening.

Primary outcomes:
measure: Blood pressure measurements.
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan University
state: Missouri
Study officials:
affiliation: Logan University
name: John Zhang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05832658: Efficacy of Game-Based EMG-Biofeedback Therapy in Post-Stroke Dysphagia
Official title: Efficacy of Game-Based EMG-Biofeedback Therapy in Post-Stroke Dysphagia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Dysphagia
Surface Electromyography
Biofeedback
Swallowing Disorder
Lead sponsor: Kocaeli University
Sponsor class: OTHER
First posted: 2023-04-27
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to determine the effectiveness of game-based biofeedback application via surface electromyography in patients with post-stroke dysphagia. The same treatment interventions will be applied with and without biofeedback, and thus the contribution of adding biofeedback to the treatment will be determined.


Eligibility criteria: Inclusion Criteria:

1. History of hemorrhagic or ischemic stroke longer than 3 months
2. Being over the age of eighteen
3. Level ≤ 6 on the Functional Oral Intake Scale (FOIS)
4. Post-stroke onset of swallowing complaints
5. Ability to communicate with the patient and carry out the given commands
6. Mini mental test evaluation ≥ 24 points
7. Absence of concomitant serious systemic disease (unregulated hypertension, decompensated heart failure, malignancy, infection, pacemaker, epilepsy, etc.)
8. Detection of pathology in the oropharyngeal phase of swallowing in videofluoroscopic evaluation
9. Not taking any swallowing-related treatment in the last 3 months

Exclusion Criteria:

1. History of neoplastic disease and/or radiotherapy to the head and neck region
2. Having additional musculoskeletal disease or non-stroke neurologic disease that may cause swallowing disorders
3. Unable to communicate or carry out commands
4. Inability to maintain head-holding balance
5. Patients with severe pathology in bolus formation or delivery of the bolus to the pharynx during the oral swallowing phase

Primary outcomes:
measure: Gugging Swallowing Screen (GUSS)
timeFrame: From baseline to the end of the treatment ( 3 week)
measure: Functional Oral Intake Scale (FOIS)
timeFrame: From baseline to the end of the treatment ( 3 week)
measure: Penetration Aspiration Scale (PAS)
timeFrame: From baseline to the end of the treatment ( 3 week)
measure: Functional Dysphagia Scale (FDS)
timeFrame: From baseline to the end of the treatment ( 3 week)
measure: Dysphagia Outcome and Severity Scale (DOSS)
timeFrame: From baseline to the end of the treatment ( 3 week)
measure: Dysphagia Handicap Index (DHI)
timeFrame: From baseline to the end of the treatment ( 3 week)
Secondary outcomes:
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli University
Study officials:
References:
Clinical trial NCT04134858: The Effects of Health Coaching for Frequent Attenders
Official title: The Effectiveness of Health Coaching for Frequent Attenders in the Primary Healthcare
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Health Behavior
Keywords: coaching
primary health care
Lead sponsor: University of Oulu
Sponsor class: OTHER
First posted: 2019-10-22
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The experimental and control group
Primary purpose: TREATMENT

Brief summary: The purpose of the study was to describe and evaluate the effectiveness of health coaching on health-related quality of life, adherence to health regimens, clinical health outcomes and lifestyle factors among frequent attenders in primary healthcare.

Detailed description: The quasi-experimental research method evaluated the effectiveness of health coaching among frequent attenders in primary healthcare. The experimental group received the health coaching and the control group received the usual care. The data were collected with pre- and posttest 12-month follow-up via a questionnaire of FINRISKI2012, RAND-36 and ACDI and clinical health outcomes measured by health-coaching nurses. The data were analyzed by statistical methods.

Eligibility criteria: Inclusion Criteria:

* Patients who had face-to-face visits to the physicians in the local primary healthcare centre at least seven times during a 12-month period
* Aged 18 years or older
* Able to read and understand Finnish

Exclusion Criteria:

* Patients´ visits due to pregnancy or delivery
* Patients´ visits due to serial treatment for the same disease
* An inability to give informed consent
* Involving in another study intervention at the same time

Primary outcomes:
measure: The health-related quality of life
timeFrame: 12 months
measure: Adherence to health regimens
timeFrame: 12 months
Secondary outcomes:
measure: Lifestyle factors
timeFrame: 12 months
Other outcomes:
measure: The clinical health outcomes: Weight
timeFrame: 12 months
measure: The clinical health outcomes: Height
timeFrame: 12 months
measure: The clinical health outcomes: Body mass index (BMI)
timeFrame: 12 months
measure: The clinical health outcomes: Blood pressure
timeFrame: 12 months
Locations:
Study officials:
affiliation: University of Oulu
name: Maria Kääriäinen, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04548258: Bone Changes Assessment in Screw-Retained Maxillary Complete Denture With Electric Welded Framework Versus Cast One
Official title: Bone Changes Assessment in Screw-Retained Maxillary Implant Supported Complete Denture With Electric Welded Metal Framework Versus Cast One (Randomized Control,Split Mouth Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bone Resorption
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-09-14
Enrollment: 12
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: comparing bony changes around implants that will be joined by ametal framework either with electric weiling or with the conventional casting metal

Detailed description: joining multiple implants together in the edentulous arches is considered agood solution, using the conventional casting technique has many disadvantages due to lab errors and time and cost consuming on ,the other hand the study aims to owercome these disadvantages using electric welding metal framework.

Eligibility criteria: Inclusion Criteria:

* Age range from 30 to 65 years old.
* Absence of any medical disorder that could complicate the Surgical phase or affect osseointegration.
* The patients must be completely edentulous.
* The patient must have enough bone height for implants minimum length of 10mm and a minimum diameter of 5 mm.
* Patients with good oral hygiene.
* Complete denture wearer.
* Adequate inter arch space for screw retained prosthesis.
* Absence of any intra-oral pathological condition.

Exclusion Criteria:

Patients with recent extraction(less than three months).

* Patients with inflamed ridge or candida infection.
* Patients with flappyridge.
* Parafunctional habits.

Primary outcomes:
measure: bony changes assessment
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University ,Faculty of Dentistry
Study officials:
References:
Clinical trial NCT03612258: Brain Mechanisms of Juvenile Fibromyalgia
Official title: Brain Mechanisms of Altered Sensory Perception and Self-Referential Processing in Juvenile Fibromyalgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fibromyalgia
Keywords: Fibromyalgia
Pain
Neuroimaging
Sensory sensitivity
Fatigue
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor class: OTHER
First posted: 2018-08-02
Enrollment: 153
Sex: FEMALE
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study evaluates whether differences exist between adolescent females with juvenile-onset fibromyalgia and healthy controls in processing of pain and emotion at the neural level as assessed by functional magnetic resonance imaging (fMRI). The study includes a longitudinal component to evaluate changes in neural processing of pain and emotion before and after different treatment strategies.

Detailed description: Juvenile-onset fibromyalgia (JFM) is a chronic, widespread pain condition that primarily affects females. Previous work has shown increased sensitivity to painful and non-painful sensory stimuli in adults with fibromyalgia, as well as brain processing abnormalities associated with these stimuli. These abnormalities in adults are highly predictive of fibromyalgia status (as opposed to healthy status) in adults. Although JFM has some similar symptoms and features to fibromyalgia in adults, the neural mechanisms of JFM may be partially different, given the moment of sharp brain development characterising JFM. fMRI scans will be completed before and after different treatments for JFM (e.g. neuromuscular training + cognitive behavioral therapy, graded aerobic exercise) to investigate the effects of treatment on brain measures related to pain, fatigue and emotion processing.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Juvenile Fibromyalgia (by a pediatric rheumatologist or pain physician using 2010 American College of Rheumatology criteria)
* Right handed
* Functional Disability Index score ≥ 7, indicating at least mild disability
* Stable medication regimen for 3 weeks prior to MRI scan

Exclusion Criteria:

* Non-MRI compatible metal objects in the body (including braces, permanent upper retainers)
* Comorbid rheumatic disease (e.g. juvenile arthritis, systemic lupus erythematosus)
* Major psychiatric diagnoses (e.g. bipolar disorder, obsessive compulsive disorder, schizophrenia) or documented developmental delay
* Taking opioid pain medication

Primary outcomes:
measure: Functional brain activation differences
timeFrame: Baseline
Secondary outcomes:
measure: Functional brain activation differences
timeFrame: Baseline and 8 weeks
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
Study officials:
affiliation: Children's Hospital Medical Center, Cincinnati
name: Robert Coghill, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04329858: the Antibacterial Effect of Zinc ,Silver and Fluoride
Official title: the Antibacterial Effect of Different Glass Ionomer Restoration Containing Zinc ,Silver and Fluoride Ion:in Situ Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dental Caries
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-04-01
Enrollment: 50
Sex: ALL
Minimum age (years): 10
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: natural teeth will be filled with the 3 different material then the dentin sample will be collected ,bacterial culture and elementary analysis will be done

Detailed description: orthodontic patient with premolar indicated for extraction , teeth will restored with the different material 3 months before doing extraction

Eligibility criteria: Inclusion Criteria:

* patient need teeth extraction for orthodontic treatment

Exclusion Criteria:

* carious teeth deciduous teeth

Primary outcomes:
measure: bacterial count
timeFrame: 3months
measure: elementary analysis of dentin
timeFrame: 3months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: